One cycle
every 21 days × 6 · about 18 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
| 1.8 mg/kg | IV | D1 | ||
Rituximab Monoclonal antibody (anti-CD20, chimeric) | 375 mg/m² | IV | D1 | |
Cyclophosphamide Alkylating agent (oxazaphosphorine prodrug) | 750 mg/m² | IV | D1 | |
Doxorubicin Cytotoxic chemotherapy (anthracycline) | 50 mg/m² | IV | D1 | |
Prednisone | 100 mg once daily | Oral | D1-5 |
Cycles
6, then rituximab alone cycles 7-8
21-day cycle
Emetogenicity
Moderate (30-90%)
G-CSF
Recommended
Notes
- Vincristine is replaced by polatuzumab; G-CSF primary prophylaxis was mandated in POLARIX.
Used in
Trials
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
R-CHOP
Diffuse large B-cell lymphoma, first line (6 cycles; 3-4 with radiotherapy for limited stage)
every 21 days × 6
R-ICE
Relapsed or refractory DLBCL, salvage before autologous transplant (late relapse) or bridging
every 14 days × 2-3
Fludarabine + cyclophosphamide lymphodepletion, then CD19 CAR-T
Relapsed or refractory large B-cell lymphoma (second line if refractory or relapse within 12 months), B-ALL, follicular and mantle cell lymphoma
every 6 days